Abatacept now available on NHS for rheumatoid arthritis

NICE has overturned its original decision to reject the rheumatoid arthritis treatment abatacept (Orencia).

Abatacept inhibits the activation of T cells, a key step in the development of rheumatoid arthritis.
Abatacept inhibits the activation of T cells, a key step in the development of rheumatoid arthritis.

In a review of its 2008 guidance, the institute has ruled that abatacept, in combination with methotrexate, can be considered for adults with severe active rheumatoid arthritis who are unresponsive or intolerant to a DMARD (including at least one TNF inhibitor) and in whom rituximab is unsuitable.

Adalimumab, etanercept and infliximab are recommended as other treatment options alongside abatacept.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Further drug shortages prompt advice to consider unlicensed alternatives

Further drug shortages prompt advice to consider unlicensed alternatives

Prescribers are being advised to prioritise supplies...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Anusol Ointment, isoniazid, Synphase.
Use...

Vaping still safer than smoking, say health bosses after report of severe lung injury
Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

Free online vestibular rehabilitation tool 'highly effective' for vertigo symptoms

GPs should consider online vestibular rehabilitation...